The Association Between Serum Adiponectin Level and Glycemic Control

Aim: In last decades we recognize that the fat tissue isn%u2019t only a depot also an active endocrine tissue. The fat cell isn%u2019t a passive cell, it has an unsteady volume that changes according to daily energy uptake, and releases cytokines and hormones to extracelluler fluid. Patients with type 2 diabetes have distinctly increased atherosclerotic risk. This risk is associated with hyperglycemia, dyslipidemia and increased inflamation. Adiponectine that only secretes from adipose tissue, has a suspected role in this process. In this trial we looked for if there is any effect of adiponectin on glycemic control. Material and Method: The patients had been divided in three groups; diabetics with good glycemic control (n:20), diabetics with bad glycemic control (n:34) and non diabetics (n:19). All patients age, sex, history of diabetes, BMI, waist circumference, fat mass, fat % had recorded then serums had taken for adiponectin and HbA1c assesment. Results: There was no correlation with adiponectine and HbA1c. Serum adiponectine levels were similar in three groups (659,2998,57; 694,09144,85; 609,5168,24; p:0,117). Discussion: The results showed that there is no significant effect of adiponectin on glycemic control contrary to expectations. The low levels of serum adiponectin isn%u2019t cause of the metabolic syndrome and insulin resistance, it%u2019s the result of the process that results in metabolic syndrome.